Profile
Michal Ayalon worked as Vice President of Research and Development at Kamada Ltd.
from 2019 to 2022.
Prior to that, she held the same position at Galmed Pharmaceuticals Ltd.
in 2015-2016.
In 2018-2019, she was Head of Research and Development at 89Bio Ltd.
Ayalon received her undergraduate, graduate, and doctorate degrees from Tel-Aviv University.
Former positions of Michal Ayalon
| Companies | Position | End |
|---|---|---|
| KAMADA LTD. | Chief Tech/Sci/R&D Officer | 27/02/2022 |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Chief Tech/Sci/R&D Officer | 31/12/2018 |
| GALMED PHARMACEUTICALS LTD. | Chief Tech/Sci/R&D Officer | 31/12/2015 |
Training of Michal Ayalon
| Tel-Aviv University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| KAMADA LTD. | Health Technology |
| GALMED PHARMACEUTICALS LTD. | Health Technology |
| Private companies | 1 |
|---|---|
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Health Technology |
- Stock Market
- Insiders
- Michal Ayalon
